BioSpace News Archive

There has been something of a furor over reports in the German newspaper Welt am Sonntag that claimed the Trump administration offered a “billion dollars” for exclusive rights to a coronavirus vaccine in development by German company CureVac, “but only for the USA.”

Work in the age of COVID-19 is in flux. Restrictions change daily, and life sciences researchers are finding their work lives considerably different than they were a few short weeks ago.

‘Flatten the Curve’ is sure to become a phrase forever linked with COVID-19. It refers to doing all we can as individuals to slow the spread of COVID-19 so that all available resources can be used for those who need them most urgently.

Approximately 100 cases of COVID-19 have been linked to a Biogen corporate meeting, as reported by a local media station in the Boston area.

Researchers found fear of testing new treatments and possible side effects were common denominators among patients.

Zai Lab Limited announced the China National Medical Products Administration has accepted its supplemental New Drug Application for ZEJULA® as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

Haselmeier officially announces that it has received Master File Number MAF3202 from the Food and Drug Administration of the United States for its D-Flex product platform, a new generation of injection pen systems for subcutaneous self-administration.

Pfizer Inc. and BioNTech SE announced that the companies have agreed to a letter of intent regarding the co-development and distribution of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection.

Compassionate care protocol to be conducted at Rambam Healthcare Campus in coordination with the Government of Israel

First global clinical confirmation of a live biotherapeutic product initiating a response in cancer patients